Analytical Data
-
Gene name
IFNW1
- Application
-
Alternative Names
IFNW1；Interferon omega-1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P05000
-
Expression Region
1-195aa
-
AA Sequence
MALLFPLLAA LVMTSYSPVG SLGCDLPQNH GLLSRNTLVL LHQMRRISPF LCLKDRRDFR FPQEMVKGSQ LQKAHVMSVL HEMLQQIFSL FHTERSSAAW NMTLLDQLHT GLHQQLQHLE TCLLQVVGEG ESAGAISSPA LTLRRYFQGI RVYLKEKKYS DCAWEVVRME IMKSLFLSTN MQERLRSKDR DLGSS
-
Molecular Weight
22 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IFNW1 (Interferon lambda 1) is a cytokine that plays a critical role in the immune response, especially against viral infections. It belongs to the type III interferon family, which includes IFNL1, IFNL2, and IFNL3. Unlike other interferons, IFNW1 primarily interacts with specific receptors on epithelial and immune cells, facilitating antiviral responses and influencing inflammation. Research on IFNW1 has gained momentum due to its potential therapeutic applications in various diseases, including viral hepatitis, cancer, and autoimmune disorders. Studies have shown that IFNW1 can enhance the antiviral activity of immune cells and promote the regeneration of infected tissues. Scientists are particularly interested in the development of recombinant IFNW1 proteins to explore their efficacy as therapeutic agents. These recombinant proteins can be engineered to improve stability, potency, and delivery methods, offering promising strategies for treating diseases where immune modulation is desirable. As our understanding of the mechanisms underlying IFNW1's actions expands, the potential for developing targeted therapies based on this cytokine becomes increasingly significant, paving the way for innovative treatments in the field of immunotherapy and infectious diseases.
